SCHEMBL16815495

SCHEMBL16815495

COC(OC)c1ccnc(-c2ccoc2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ KMT2A Q03164 12/20 0.50
▸ MAPT P10636 6/20 0.50
▸ RAB9A P51151 1/20 0.49
▸ CYP1A2 P05177 11/20 0.46
▸ CYP2D6 P10635 9/20 0.46
▸ HSD17B10 Q99714 8/20 0.46
▸ ALDH1A1 P00352 6/20 0.46
▸ ALOX15 P16050 6/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ CYP3A4 P08684 9/20 0.44
▸ USP2 O75604 8/20 0.44
▸ MEN1 O00255 8/20 0.44
▸ TP53 P04637 1/20 0.44
▸ CYP2C19 P33261 8/20 0.44
▸ TSHR P16473 3/20 0.44
▸ TDP1 Q9NUW8 3/20 0.44
▸ CYP2C9 P11712 3/20 0.44
▸ MAPK1 P28482 3/20 0.43
▸ CLK4 Q9HAZ1 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16815686 0.79 SMN1; SMN2 (0.62) SMN1; SMN2KMT2AMAPTRAB9ACYP1A2
SCHEMBL16816242 0.76 SMN1; SMN2 (0.63) SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1
SCHEMBL20745058 0.76 SMN1; SMN2 (0.68) SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1
SCHEMBL30440564 0.76 CYP1A2 (0.50) SMN1; SMN2KMT2AMAPTCYP1A2CYP2D6
SCHEMBL25275555 0.76 CYP1A2 (0.50) SMN1; SMN2KMT2AMAPTCYP1A2CYP2D6
SCHEMBL16815718 0.74 SMN1; SMN2 (0.53) SMN1; SMN2KMT2AMAPTRAB9ACYP1A2
SCHEMBL20745566 0.74 SMN1; SMN2 (0.60) SMN1; SMN2KMT2AMAPTRAB9ACYP1A2
SCHEMBL16815276 0.74 SMN1; SMN2 (0.53) SMN1; SMN2KMT2AMAPTRAB9ACYP1A2
SCHEMBL25719745 0.73 CYP1A2 (0.53) SMN1; SMN2KMT2AMAPTCYP1A2CYP2D6
SCHEMBL30456395 0.72 CYP1A2 (0.49) SMN1; SMN2KMT2AMAPTCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2019-07-04 — — US disclosed
US-10278972-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2019-05-07 — — US disclosed
US-20170216293-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2017-08-03 — — US disclosed
US-9670227-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2017-06-06 — — US disclosed
EP-2886545-B1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2016-06-29 — — EP disclosed
WO-2015097123-A1 NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2015-07-02 — — WO disclosed
US-20150175623-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2015-06-25 — — US disclosed
EP-2886545-A1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2015-06-24 — — EP disclosed
CN-104725397-A Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB 2015-06-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216293-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 SMN1; SMN2 1945/4885KMT2A 3050/4885MAPT 2702/4885
US-10278972-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them TYMS, TYMP, TPX2 SMN1; SMN2 1945/4885KMT2A 3050/4885MAPT 2702/4885
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 SMN1; SMN2 1945/4885KMT2A 3050/4885MAPT 2702/4885
US-20150175623-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 SMN1; SMN2 1945/4885KMT2A 3050/4885MAPT 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback